Available in Chile, Brazil, Mexico
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel
group study to evaluate the safety and efficacy of tezepelumab in adults with moderate to
very severe chronic obstructive pulmonary disease (COPD) receiving inhaled maintenance
therapy and having had at least 2 moderate, or 1 severe, COPD exacerbations in the 12
months prior to Visit 1. Subjects will receive monthly subcutaneous injection of one of
two different doses of tezepelumab, or placebo, with a maximum treatment duration of 76
weeks and a minimum of 52 weeks. The study also includes a off-treatment safety follow-up
period of 12 weeks.
990Patients around the world